Clinical Trials on HER2

Total 986 results

University of Washington
National Cancer Institute (NCI)

Active, not recruiting

Vaccine Therapy With Sargramostim (GM-CSF) in Treating Patients With Her-2 Positive Stage III-IV Breast Cancer or Ovarian Cancer

HER2-positive Breast Cancer | Stage IV Breast Cancer | Stage IV Ovarian Epithelial Cancer | Stage IV Ovarian Germ Cell Tumor | Stage IIIA Breast Cancer | Stage IIIB Breast Cancer | Stage IIIC Breast Cancer | Stage III Ovarian Epithelial Cancer | Stage III Ovarian Germ Cell Tumor

United States
Fusion Pharmaceuticals Inc.

Recruiting

A Phase 1/2 Study of [225Ac]-FPI-1434 Injection

Cervical Cancer | Breast Cancer | Ovarian Cancer | Endometrial Cancer | Uveal Melanoma | Adrenocortical Carcinoma | Advanced Solid Tumours | HER2-negative Breast Cancer | Triple Negative Breast Cancer (TNBC) | Head and Neck Squamous Cell Carcinoma (HNSCC)

United States, Australia, Canada
National Cancer Institute (NCI)

Completed

Veliparib in Treating Patients With Malignant Solid Tumors That Do Not Respond to Previous Therapy

Recurrent Fallopian Tube Carcinoma | Recurrent Ovarian Carcinoma | Recurrent Primary Peritoneal Carcinoma | Breast Carcinoma | Ovarian Carcinoma | Pancreatic Carcinoma | Prostate Carcinoma | Recurrent Breast Carcinoma | Estrogen Receptor Negative | HER2/Neu Negative | Progesterone Receptor Negative | Triple-Negative... and other conditions

United States
Seagen Inc.

Recruiting

A Study of SGN-B7H4V in Advanced Solid Tumors

Carcinoma, Non-Small-Cell Lung | Adenoid Cystic Carcinoma | Ovarian Neoplasms | Fallopian Tube Neoplasms | Peritoneal Neoplasms | Endometrial Neoplasms | Cholangiocarcinoma | Triple Negative Breast Neoplasms | Gallbladder Carcinoma | HER2 Negative Breast Neoplasms | Hormone Receptor Positive Breast Neoplasms

United States, Spain, Canada, United Kingdom, Germany, Italy
German Breast Group
Roche Pharma AG; Celgene Corporation

Completed

Nanoparticle-based Paclitaxel vs Solvent-based Paclitaxel as Part of Neoadjuvant Chemotherapy for Early Breast Cancer (GeparSepto) (GeparSepto)

Inflammatory Breast Cancer | HER-2 Positive Breast Cancer | Tubular Breast Cancer Stage II | Mucinous Breast Cancer Stage II | Breast Cancer Female NOS | Invasive Ductal Breast Cancer | Tubular Breast Cancer Stage III | Inflammatory Breast Cancer Stage IV

Germany
German Breast Group
GlaxoSmithKline; Roche Pharma AG; Teva Pharmaceuticals USA

Completed

Addition of Carboplatin to Neoadjuvant Therapy for Triple-negative and HER2-positive Early Breast Cancer (GeparSixto)

Inflammatory Breast Cancer | HER-2 Positive Breast Cancer | Tubular Breast Cancer Stage II | Mucinous Breast Cancer Stage II | Breast Cancer Female NOS | Invasive Ductal Breast Cancer | Tubular Breast Cancer Stage III | Inflammatory Breast Cancer Stage IV

Germany
Abramson Cancer Center of the University of Pennsylvania

Completed

Phase II Trial of the Cyclin-Dependent Kinase Inhibitor PD 0332991 in Patients With Cancer

Adult Solid Tumor | HER2-positive Breast Cancer | Recurrent Melanoma | Male Breast Cancer | Stage IV Breast Cancer | Stage IV Melanoma | Stage IV Ovarian Germ Cell Tumor | Recurrent Breast Cancer | Estrogen Receptor-negative Breast Cancer | Estrogen Receptor-positive Breast Cancer | Progesterone Receptor-negative... and other conditions

United States
NeoTX Therapeutics Ltd.
AstraZeneca

Active, not recruiting

Naptumomab Estafenatox in Combination With Durvalumab in Subjects With Selected Advanced or Metastatic Solid Tumors

Melanoma | Renal Cell Carcinoma | Hepatocellular Carcinoma | Pancreatic Adenocarcinoma | Ovarian Cancer | NSCLC | Prostate Cancer | Mesothelioma | Bladder Cancer | Triple Negative Breast Cancer | Endometrial Cancer | Colorectal Cancer Metastatic | Head and Neck Squamous Cell Carcinoma | Urothelial Cancer | Cervical Squamous... and other conditions

Israel
M.D. Anderson Cancer Center
National Cancer Institute (NCI)

Completed

Mirvetuximab Soravtansine as First Line in Treating Patients With Triple Negative Breast Cancer

Anatomic Stage II Breast Cancer AJCC v8 | Anatomic Stage IIA Breast Cancer AJCC v8 | Anatomic Stage IIB Breast Cancer AJCC v8 | Anatomic Stage III Breast Cancer AJCC v8 | Anatomic Stage IIIA Breast Cancer AJCC v8 | Anatomic Stage IIIB Breast Cancer AJCC v8 | Anatomic Stage IIIC Breast Cancer AJCC... and other conditions

United States
Universitair Ziekenhuis Brussel
Kom Op Tegen Kanker; Agentschap voor Innovatie door Wetenschap en Technologie...

Recruiting

Repeatability of 68-GaNOTA-Anti-HER2 VHH1 PET/CT in Breast Carcinoma Patients (VUBAR)

Gastric Cancer | Colorectal Cancer | Prostate Cancer | Non Small Cell Lung Cancer | Cholangiocarcinoma | Endometrial Cancer | Urothelial Carcinoma | Biliary Tract Cancer | Locally Advanced Breast Cancer | Cancer of Pancreas | Uterine Cancer | Salivary Gland Cancer | Metastatic Breast Carcinoma | Solid Tumor With Intermediate...

Belgium
OHSU Knight Cancer Institute
Eli Lilly and Company; GlaxoSmithKline; Oregon Health and Science University

Active, not recruiting

Abemaciclib and Niraparib Before Surgery for the Treatment of Hormone Receptor Positive HER2 Negative Breast Cancer

Anatomic Stage I Breast Cancer AJCC v8 | Anatomic Stage IA Breast Cancer AJCC v8 | Anatomic Stage IB Breast Cancer AJCC v8 | Anatomic Stage II Breast Cancer AJCC v8 | Anatomic Stage IIA Breast Cancer AJCC v8 | Anatomic Stage IIB Breast Cancer AJCC v8 | Anatomic Stage IIIA Breast Cancer AJCC v8 | Prognostic... and other conditions

United States
Mayo Clinic
National Cancer Institute (NCI)

Active, not recruiting

Rifaximin for the Treatment of Gastrointestinal Toxicities Related to Pertuzumab-Based Therapy in Patients With Stage I-III HER2 Positive Breast Cancer

Anatomic Stage I Breast Cancer AJCC v8 | Anatomic Stage IA Breast Cancer AJCC v8 | Anatomic Stage IB Breast Cancer AJCC v8 | Anatomic Stage II Breast Cancer AJCC v8 | Anatomic Stage IIA Breast Cancer AJCC v8 | Anatomic Stage IIB Breast Cancer AJCC v8 | Anatomic Stage III Breast Cancer AJCC v8 | Anatomic... and other conditions

United States
Roswell Park Cancer Institute
National Center for Advancing Translational Sciences (NCATS)

Completed

Chemokine Modulation Therapy and Standard Chemotherapy Before Surgery for the Treatment of Early Stage Triple Negative Breast Cancer

Anatomic Stage I Breast Cancer AJCC v8 | Anatomic Stage IA Breast Cancer AJCC v8 | Anatomic Stage IB Breast Cancer AJCC v8 | Anatomic Stage II Breast Cancer AJCC v8 | Anatomic Stage IIA Breast Cancer AJCC v8 | Anatomic Stage IIB Breast Cancer AJCC v8 | Prognostic Stage I Breast Cancer AJCC v8 | Prognostic... and other conditions

United States
ProfoundBio US Co.

Recruiting

PRO1184 for Advanced Solid Tumors (PRO1184-001)

Ovarian Cancer | Fallopian Tube Cancer | Mesothelioma | Triple Negative Breast Cancer | Endometrial Cancer | Non-small Cell Lung Cancer | Primary Peritoneal Carcinoma | Breast Adenocarcinoma | High Grade Epithelial Ovarian Cancer | Hormone Receptor-positive/Her2 Negative Breast Cancer

United States, China
Alliance for Clinical Trials in Oncology
National Cancer Institute (NCI); Seagen Inc.

Recruiting

T-DM1 and Tucatinib Compared With T-DM1 Alone in Preventing Relapses in People With High Risk HER2-Positive Breast Cancer, the CompassHER2 RD Trial

Anatomic Stage IA Breast Cancer AJCC v8 | Anatomic Stage II Breast Cancer AJCC v8 | Anatomic Stage IIA Breast Cancer AJCC v8 | Anatomic Stage IIB Breast Cancer AJCC v8 | Anatomic Stage III Breast Cancer AJCC v8 | Anatomic Stage IIIA Breast Cancer AJCC v8 | Anatomic Stage IIIB Breast Cancer AJCC... and other conditions

United States, Canada, Puerto Rico
Seagen Inc.

Terminated

A Study of SGN-STNV in Advanced Solid Tumors

Uterine Cervical Neoplasms | Stomach Neoplasms | Colorectal Neoplasms | Esophageal Neoplasms | Ovarian Neoplasms | Endometrial Neoplasms | Pseudomyxoma Peritonei | Carcinoma, Non-Small Cell Lung | Gastroesophageal Junction Carcinoma | HER2 Negative Breast Neoplasms | Exocrine Pancreatic Adenocarcinoma | Appendiceal...

United States, United Kingdom, Canada, Spain, France, Italy
City of Hope Medical Center
National Cancer Institute (NCI)

Active, not recruiting

Vaccine Therapy and Pembrolizumab in Treating Patients With Solid Tumors That Have Failed Prior Therapy

Melanoma | Soft Tissue Sarcoma | Renal Cell Carcinoma | Hepatocellular Carcinoma | Head and Neck Squamous Cell Carcinoma | Bladder Carcinoma | Colon Carcinoma | Pancreatic Carcinoma | Rectal Carcinoma | Estrogen Receptor Negative | HER2/Neu Negative | Progesterone Receptor Negative | Triple-Negative Breast Carcinoma and other conditions

United States
M.D. Anderson Cancer Center
National Cancer Institute (NCI)

Completed

Atorvastatin in Treating Patients With Stage IIb-III Triple Negative Breast Cancer Who Did Not Achieve a Pathologic Complete Response After Receiving Neoadjuvant Chemotherapy

Anatomic Stage IIB Breast Cancer AJCC v8 | Anatomic Stage III Breast Cancer AJCC v8 | Anatomic Stage IIIA Breast Cancer AJCC v8 | Anatomic Stage IIIB Breast Cancer AJCC v8 | Anatomic Stage IIIC Breast Cancer AJCC v8 | Prognostic Stage IIB Breast Cancer AJCC v8 | Prognostic Stage III Breast Cancer... and other conditions

United States
University of Washington
National Cancer Institute (NCI)

Completed

Cyclophosphamide or Denileukin Diftitox Followed By Expanding a Patient's Own T Cells in the Laboratory in Treating Patients With HER-2/Neu Overexpressing Metastatic Breast Cancer, Ovarian Cancer, or Non-Small Cell Lung Cancer Previously Treated With HER-2/Neu Vaccine

HER2-positive Breast Cancer | Stage IV Breast Cancer | Stage IV Ovarian Epithelial Cancer | Stage IV Ovarian Germ Cell Tumor | Recurrent Breast Cancer | Recurrent Ovarian Epithelial Cancer | Recurrent Non-small Cell Lung Cancer | Stage IV Non-small Cell Lung Cancer | Recurrent Ovarian Germ Cell Tumor

United States
Seagen Inc.

Recruiting

A Study of SGN-B6A in Advanced Solid Tumors

Uterine Cervical Neoplasms | Stomach Neoplasms | Urinary Bladder Neoplasms | Ovarian Neoplasms | Squamous Cell Carcinoma of Head and Neck | Carcinoma, Non-Small Cell Lung | Esophageal Adenocarcinoma | Esophageal Squamous Cell Carcinoma | Gastroesophageal Junction Adenocarcinoma | HER2 Negative Breast Neoplasms and other conditions

United States, Spain, United Kingdom, France, Switzerland
Fate Therapeutics

Terminated

Long-term, Non-interventional, Observational Study Following Treatment With Fate Therapeutics FT500 Cellular Immunotherapy

Melanoma | Lymphoma | Renal Cell Carcinoma | Cervical Cancer | Head and Neck Cancer | Hepatocellular Carcinoma | Gastric Cancer | Colorectal Cancer | NSCLC | Advanced Solid Tumor | Small-cell Lung Cancer | HER2-positive Breast Cancer | Pancreas Cancer | Urothelial Carcinoma | Merkel Cell Carcinoma | Microsatellite Instability and other conditions

United States
Andrei Iagaru
National Cancer Institute (NCI)

Completed

18F-FSPG PET/CT for Cancer Patients on Therapy

Stage IIIA Non-Small Cell Lung Cancer | Stage IIIB Non-Small Cell Lung Cancer | Metastatic Renal Cell Cancer | Stage III Renal Cell Cancer | Stage IV Non-Small Cell Lung Cancer | Stage IV Breast Cancer | B-Cell Neoplasm | Stage IIIA Breast Cancer | Stage IV Renal Cell Cancer | Stage IIIC Breast Cancer | Estrogen... and other conditions

United States
Jonsson Comprehensive Cancer Center
National Cancer Institute (NCI)

Terminated

Ipilimumab, Nivolumab, and Talimogene Laherparepvec Before Surgery in Treating Participants With Localized, Triple-Negative or Estrogen Receptor Positive, HER2 Negative Breast Cancer-deleted

Anatomic Stage I Breast Cancer AJCC v8 | Anatomic Stage IA Breast Cancer AJCC v8 | Anatomic Stage IB Breast Cancer AJCC v8 | Anatomic Stage II Breast Cancer AJCC v8 | Anatomic Stage IIA Breast Cancer AJCC v8 | Anatomic Stage IIB Breast Cancer AJCC v8 | Anatomic Stage IIIA Breast Cancer AJCC v8 | Anatomic... and other conditions

United States
Fate Therapeutics

Completed

FT500 as Monotherapy and in Combination With Immune Checkpoint Inhibitors in Subjects With Advanced Solid Tumors

Melanoma | Lymphoma | Renal Cell Carcinoma | Cervical Cancer | Head and Neck Cancer | Small Cell Lung Cancer | Hepatocellular Carcinoma | Gastric Cancer | Colorectal Cancer | NSCLC | Advanced Solid Tumors | HER2-positive Breast Cancer | Pancreas Cancer | Urothelial Carcinoma | Merkel Cell Carcinoma | Microsatellite Instability and other conditions

United States
M.D. Anderson Cancer Center
National Cancer Institute (NCI)

Completed

IACS-010759 in Advanced Cancers

Anatomic Stage III Breast Cancer AJCC v8 | Anatomic Stage IIIA Breast Cancer AJCC v8 | Anatomic Stage IIIB Breast Cancer AJCC v8 | Anatomic Stage IIIC Breast Cancer AJCC v8 | Prognostic Stage III Breast Cancer AJCC v8 | Prognostic Stage IIIA Breast Cancer AJCC v8 | Prognostic Stage IIIB Breast... and other conditions

United States
Emory University
Novartis

Terminated

Pharmacokinetically Guided Everolimus in Patients With Breast Cancer, Pancreatic Neuroendocrine Tumors, or Kidney Cancer

Mucositis | Stage III Renal Cell Cancer | Stage IV Breast Cancer | Stage IIIA Breast Cancer | Stage IIIB Breast Cancer | Gastrinoma | Glucagonoma | Insulinoma | Pancreatic Polypeptide Tumor | Recurrent Islet Cell Carcinoma | Somatostatinoma | Stage IV Renal Cell Cancer | Recurrent Renal Cell Cancer | Stage IIIC Breast... and other conditions

United States
National Cancer Institute (NCI)

Withdrawn

Talazoparib in Treating Patients With Advanced or Metastatic Solid Tumors That Cannot Be Removed by Surgery and Liver or Kidney Dysfunction

Stage IIIA Non-Small Cell Lung Cancer | Stage IIIB Non-Small Cell Lung Cancer | Head and Neck Squamous Cell Carcinoma | Stage IV Non-Small Cell Lung Cancer | Metastatic Pancreatic Adenocarcinoma | Estrogen Receptor Negative | HER2/Neu Negative | Progesterone Receptor Negative | Triple-Negative Breast... and other conditions
BeiGene

Recruiting

A Study to Examine the Safety of Different Doses of BG-68501 Given to Participants With Advanced-Stage Tumors

Breast Cancer | Small Cell Lung Cancer | Gastric Cancer | Ovarian Cancer | Prostate Cancer | Advanced Solid Tumor | Endometrial Cancer | Hormone Receptor Positive HER-2 Negative Breast Cancer | Hormone-receptor-positive Breast Cancer

United States, Australia
National Cancer Institute (NCI)

Recruiting

Measuring the Effects of Talazoparib in Patients With Advanced Cancer and DNA Repair Variations

Anatomic Stage III Breast Cancer AJCC v8 | Anatomic Stage IV Breast Cancer AJCC v8 | Advanced Pancreatic Carcinoma | Metastatic Pancreatic Carcinoma | Stage II Pancreatic Cancer AJCC v8 | Stage III Pancreatic Cancer AJCC v8 | Stage IV Pancreatic Cancer AJCC v8 | Castration-Resistant Prostate Carcinoma and other conditions

United States
Xencor, Inc.
ICON plc

Active, not recruiting

A Study of XmAb®23104 in Subjects With Selected Advanced Solid Tumors (DUET-3) (DUET-3)

Renal Cell Carcinoma | Nasopharyngeal Carcinoma | Small Cell Lung Cancer | Hepatocellular Carcinoma | Advanced Solid Tumors | Non-small Cell Lung Carcinoma | Squamous Cell Carcinoma of the Head and Neck | Cervical Carcinoma | Endometrial Carcinoma | Urothelial Carcinoma | Colorectal Carcinoma | Pancreatic Carcinoma and other conditions

United States
Mayo Clinic

Recruiting

At-Home Cancer Directed Therapy Versus in Clinic for the Treatment of Patients With Advanced Cancer

Multiple Myeloma | Myelodysplastic Syndrome | Advanced Malignant Solid Neoplasm | Advanced Pancreatic Carcinoma | Hematopoietic and Lymphoid System Neoplasm | Advanced Lung Carcinoma | Advanced Prostate Carcinoma | Advanced Glioblastoma | Advanced Gastric Carcinoma | Advanced Breast Carcinoma | Advanced Colorectal... and other conditions

United States
Pamela Munster
Pfizer; Xynomic Pharmaceuticals, Inc.

Withdrawn

Abexinostat, Palbociclib, and Fulvestrant for the Treatment of Breast or Gynecologic Cancer

Anatomic Stage III Breast Cancer AJCC v8 | Anatomic Stage IIIA Breast Cancer AJCC v8 | Anatomic Stage IIIB Breast Cancer AJCC v8 | Anatomic Stage IIIC Breast Cancer AJCC v8 | Prognostic Stage III Breast Cancer AJCC v8 | Prognostic Stage IIIA Breast Cancer AJCC v8 | Prognostic Stage IIIB Breast... and other conditions
Stanford University

Active, not recruiting

Health Care Coach Support in Reducing Acute Care Use and Cost in Patients With Cancer

Acute Myeloid Leukemia | Stage IIIA Non-Small Cell Lung Cancer | Stage IIIB Non-Small Cell Lung Cancer | Progressive Disease | Myelodysplastic Syndrome | Stage IIA Rectal Cancer | Stage IIB Rectal Cancer | Stage IIC Rectal Cancer | Stage IIIA Rectal Cancer | Stage IIIB Rectal Cancer | Stage IIIC Rectal Cancer and other conditions

United States
National Cancer Institute (NCI)

Recruiting

Testing the Combination of Two Anti-cancer Drugs, DS-8201a and AZD6738, for The Treatment of Patients With Advanced Solid Tumors Expressing the HER2 Protein or Gene, The DASH Trial

Anatomic Stage III Breast Cancer AJCC v8 | Anatomic Stage IIIA Breast Cancer AJCC v8 | Anatomic Stage IIIB Breast Cancer AJCC v8 | Anatomic Stage IIIC Breast Cancer AJCC v8 | Prognostic Stage III Breast Cancer AJCC v8 | Prognostic Stage IIIA Breast Cancer AJCC v8 | Prognostic Stage IIIB Breast... and other conditions

United States
National Cancer Institute (NCI)

Completed

RO4929097 and Capecitabine in Treating Patients With Refractory Solid Tumors

Extranodal Marginal Zone B-cell Lymphoma of Mucosa-associated Lymphoid Tissue | Nodal Marginal Zone B-cell Lymphoma | Recurrent Adult Burkitt Lymphoma | Recurrent Adult Diffuse Large Cell Lymphoma | Recurrent Adult Diffuse Mixed Cell Lymphoma | Recurrent Adult Diffuse Small Cleaved Cell Lymphoma and other conditions

United States, Canada
National Cancer Institute (NCI)
Washington University Siteman Cancer Center

Completed

7-Hydroxystaurosporine and Irinotecan Hydrochloride in Treating Patients With Metastatic or Unresectable Solid Tumors or Triple Negative Breast Cancer (Currently Accruing Only Triple-negative Breast Cancer Patients Since 6/8/2007)

Recurrent Prostate Cancer | Unspecified Adult Solid Tumor, Protocol Specific | Small Intestine Lymphoma | Recurrent Pancreatic Cancer | Stage IV Pancreatic Cancer | Recurrent Endometrial Carcinoma | Stage IV Breast Cancer | Stage IV Ovarian Epithelial Cancer | Stage IV Ovarian Germ Cell Tumor | Triple-negative... and other conditions

United States

Clinical Trials on HER2

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Mauritania

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations